Loading stock data…
Eton Pharmaceuticals (ETON)
$36.73+1.03 (+2.89%)
Market ClosedLast close Jun 29
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eton Pharmaceuticals, Inc. in the Healthcare sector is trading at $36.73 with a market capitalization of $891M. Wall Street consensus targets $45.67 (3 analysts), implying a +24.3% move over the next 12 months. The stock is currently near its 52-week high of $36.95, remaining 73.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $24.27M↑ | $21.28M↓ | $22.46M↑ | $18.93M↑ | $17.28M |
| Gross Profit | $14.73M↑ | $13.10M↑ | $7.86M↓ | $11.92M↑ | $9.86M |
| Operating Income | $2.41M↓ | $2.46M↑ | -$1.36M↑ | -$1.48M↓ | -$470,000 |
| Net Income | $1.55M↑ | $1.48M↑ | -$1.93M↑ | -$2.58M↓ | -$1.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$891.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.82%
Volume
Today's trading volume
656,048
Recent News
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is one of the best oversold growth stocks to invest in now. H.C. Wainwright lifted the price target on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) to $57 from $52 on May 15, reaffirming a Buy rating on the shares and citing the company’s elevated fiscal 2026 revenue guidance and confidence in its growth […]
Stock Market Leaders Respect The 21-Day Line. You Should Too.
During stock market uptrends, the 21-day exponential moving average has proved itself to be a strong short-term support for leading stocks.
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next
It's been a good week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, because the company has just...
Eton (ETON) Q1 2026 Earnings Call Transcript
Sean Brynjelsen: Thank you, David. The first quarter was another great quarter for Eton. On the quarterly results, it was another great quarter for Eton with $24 million in product sales, an increase of 73% year-over-year.
Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Eton Pharmaceuticals, Inc.'s Q1 2026 earnings call